NASDAQ:TCDA - Tricida Stock Price, Forecast & News

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) released its quarterly earnings data on Thursday, November, 14th. The company reported ($0.89) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.89). View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Tricida.

Tricida will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 analysts have issued twelve-month price objectives for Tricida's stock. Their forecasts range from $48.00 to $58.00. On average, they expect Tricida's share price to reach $51.50 in the next year. This suggests a possible upside of 41.8% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

News coverage about TCDA stock has trended somewhat negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tricida earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Tricida.

Tricida saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 4,040,000 shares, a decline of 7.6% from the January 15th total of 4,370,000 shares. Based on an average trading volume of 322,300 shares, the short-interest ratio is presently 12.5 days. Currently, 11.3% of the company's shares are sold short. View Tricida's Current Options Chain.

Some companies that are related to Tricida include ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH) and Mirati Therapeutics (MRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Global Blood Therapeutics (GBT), Ocular Therapeutix (OCUL), Affimed (AFMD), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP) and Fate Therapeutics (FATE).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

Tricida's stock is owned by a number of of institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (2.02%), State Street Corp (1.02%), Geode Capital Management LLC (0.73%), Driehaus Capital Management LLC (0.53%), Candriam Luxembourg S.C.A. (0.37%) and Charles Schwab Investment Management Inc. (0.31%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Alpine Woods Capital Investors LLC, New York State Common Retirement Fund, ProShare Advisors LLC and Victory Capital Management Inc.. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl. View Insider Buying and Selling for Tricida.

TCDA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Marshall Wace North America L.P., Bank of America Corp DE, Cubist Systematic Strategies LLC, Credit Suisse AG, Renaissance Technologies LLC, Barclays PLC and AQR Capital Management LLC. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $36.33.

Tricida has a market capitalization of $1.80 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

The official website for Tricida is http://www.tricida.com/.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]